# The Impact of Using Nicorandil for the Prevention of Doxorubicin-Induced Cardiotoxicity

Study · id `cardio:ct-nct07897409` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07897409](<https://clinicaltrials.gov/study/NCT07897409>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT07897409

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 146 participants.

## Technical summary

Registry record NCT07897409. Randomized; no masking; primary purpose prevention. Start 2026-12-01 (anticipated); primary completion 2027-06-01 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose prevention
- Phase: Phase 2
- Enrolled: 146 participants (planned count; ClinicalTrials.gov record NCT07897409, source copy `cardio:ctgov-nct07897409-2026-11-03`, retrieved 2026-11-18)
- Planned start: 2026-12-01 (anticipated) (ClinicalTrials.gov record NCT07897409, source copy `cardio:ctgov-nct07897409-2026-11-03`, retrieved 2026-11-18)
- Primary completion: 2027-06-01 (anticipated) (ClinicalTrials.gov record NCT07897409, source copy `cardio:ctgov-nct07897409-2026-11-03`, retrieved 2026-11-18)
- Completion: 2027-09-01 (anticipated) (ClinicalTrials.gov record NCT07897409, source copy `cardio:ctgov-nct07897409-2026-11-03`, retrieved 2026-11-18)
- Countries: Egypt (ClinicalTrials.gov record NCT07897409, source copy `cardio:ctgov-nct07897409-2026-11-03`, retrieved 2026-11-18)
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07897409-2026-11-03`, retrieved 2026-11-18)

## The registry's words

- Brief title: The Impact of Using Nicorandil for the Prevention of Doxorubicin-Induced Cardiotoxicity
- Acronym: NICBREASTRCT
- Condition: Doxorubicin Induced Cardiotoxicity
- Condition: Doxorubicin Induced Cardiomyopathy
- Condition: Doxorubicin
- Condition: Doxorubicin Adverse Reaction
- Intervention (Drug): Nicorandil Oral Tablet
- Intervention (Drug): Adriamycin (Doxorubicin)
- Lead sponsor: Universiti Sains Malaysia
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Cardiomyopathy (heart muscle disease) (`cardio:cardiomyopathy`)
- Registry lists this organization as the lead sponsor: Universiti Sains Malaysia (`cardio:org-universiti-sains-malaysia`)

## Provenance

Content hash: cf34a73b5aa2cc94eb9e1b098438e41f85db580e2d0942e0120e889761e499b6
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
